Cargando…
Survival of Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation in Patients under Rapamycin Treatment
Background: One of the important causes of mortality and morbidity in kidney transplanted patients is Post Transplant Lymphoproliferative Disease (PTLD), which is due to immunosuppression therapy and viral activity. It seems that Rapamycin, with dual antineoplastic and immunosuppressive effects, may...
Autores principales: | Ashrafi, Farzaneh, Shahidi, Shahrzad, Mehrzad, Valiollah, Mortazavi, Mojgan, Hosseini, Sayyideh Forough |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888361/ https://www.ncbi.nlm.nih.gov/pubmed/35291663 http://dx.doi.org/10.18502/ijhoscr.v15i4.7479 |
Ejemplares similares
-
Outcome of Rapamycin Therapy for Post-Transplant-Lymphoproliferative Disorder after Kidney Transplantation: Case Series
por: Ashrafi, Farzaneh, et al.
Publicado: (2015) -
Post-transplant lymphoproliferative disease after pediatric kidney transplant
por: Fulchiero, Rosanna, et al.
Publicado: (2022) -
Anticoagulation therapy in COVID-19 patients with chronic kidney disease
por: Shafiee, Mohammad Ali, et al.
Publicado: (2021) -
Post-transplant lymphoproliferative disease
por: Dharnidharka, Vikas R., et al.
Publicado: (2009) -
Comparison of polyomavirus (BK virus and JC viruses) viruria in renal transplant recipients with and without kidney dysfunction
por: Taheri, Shahram, et al.
Publicado: (2011)